In April 1990, the Chicago Tribune published a front page article entitled 'Gene therapy poised to reinvent medicine'. More than a quarter of a century later, even the most bullish scientists working in the field of gene therapy would probably acknowledge that 'the reinvention of medicine' by gene therapy has yet to be realized. Nonetheless, I think it is fair to say that we are at the cusp of using somatic gene transfer to treat, if not cure, numerous genetic and even acquired diseases. At the same time, it would be foolish to deny that formidable obstacles remain to realize fully the great potential that gene therapy provides to revolutionize the treatment of monogeneic Mendelian diseases and to use therapeutic gene transfer as an important treatment modality for complex genetic disorders and acquired diseases.
From its inception, the most daunting roadblock to successful therapeutic gene transfer has been the efficient and selective delivery of the therapeutic gene to the desired target organ(s). As Inder Verma from the Salk Institute put it: 'There are only three problems in gene therapy, delivery, delivery and delivery'. 1 Among the most promising platforms to carry therapeutic DNA payloads to their target tissue are undoubtedly vectors based on adeno-associated virus (AAV). In fact, the treatment of lipoprotein lipase deficiency by an AAV1 vector encoding the defective gene is the first gene therapy treatment approved for clinical use in the Western world. 2 Moreover, significant progress has been made toward treating numerous other diseases such as, for instance, Leber's congenital amaurosis 3 and hemophilia B with AAV-based vectors. 4 Even so, whereas we are able to correct completely many enzyme deficiencies in mice, we still struggle to achieve equal success in clinical trials. For instance, in the landmark study by Nathwani et al. 4 to treat hemophilia B, the two patients who received a high-dose injection of a self-complementary AAV8 vector (2 × 10 12 vector genomes per kg) encoding a codonoptimized factor IX reached factor IX levels of between 3% and 11% of normal levels. In contrast, mice receiving an approximately fourfold lower dose per kg of the same vector achieved supraphysiological levels of factor IX. 5 Because the patients in the clinical study of Nathwani et al. 4 were prescreened for the absence of neutralizing antibodies against AAV8, the easiest explanation for these differences is that AAV8 transduces murine hepatocytes more efficiently when compared with human hepatocytes, a view supported by experiments from Mark Kay's group. 6 How then, do we determine which AAV serotype or variant will transduce the desired human target organ most efficiently? Are studies in nonhuman primates the answer? Certainly, nonhuman primates are our most closely related species, and it is not unreasonable to assume that the tropisms of AAVs diverge less between humans and nonhuman primates when compared with tropism differences between humans and mice. As of now, however, careful biodistribution analyses in nonhuman primates are scarce, and essentially nothing is known about the tropism of the various serotypes in humans. As a result, presently we cannot assess how suitable nonhuman primates are for predicting the tropism of AAVs in humans.
How about studying the tropism of the available AAVs in isolated human primary cells? Unfortunately, if the relative efficiency of in vivo vs in vitro transduction of rat cardiomyocytes by AAV6 and AAV9 is any guidance, the answer is that isolated primary cells are of little value in predicting in vivo transduction efficiencies. In fact, whereas in vivo transduction with systemically delivered AAV9 results in much stronger transduction of cardiomyocytes compared with transduction by AAV6, the transduction of isolated adult rat cardiomyocytes is 4100-fold higher with AAV6 when compared with AAV9.
Clearly, we need novel methods to determine the tropism of AAV serotypes and variants in humans. One possible approach is to perform careful biodistribution studies in subjects that die as a result of the underlying disease during a clinical trial with an AAV vector. Of course, this method is only suitable in clinical trials where a significant mortality rate is likely. Examples of such trials include clinical trials aimed at treating late-stage cancer or heart failure. In fact, in the CUPID (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b) trial (NCT01643330), which aimed at treating heart failure by delivering the sarcoplasmatic calcium ATPase, SERCA2a, to cardiomyocytes with an AAV1 vector, the number of vector genomes was determined in patients that either died during the trial or who had undergone a cardiac procedure that allowed the collection of heart tissue. Strikingly, the biodistribution analyses 7 suggest that, in all the samples collected, o 1% of cardiomyocytes contained a vector genome. This implies that, in humans, AAV1 delivered via antegrade intracoronary infusion at the clinical doses used (1 × 10 13 vg) transduces cardiomyocytes with very low efficiency. 7 A unique opportunity to study AAV tropism presents itself if the protein to be expressed is a membrane protein, and the patients are null for the expression of this protein. In such cases, for instance when the LDL receptor (LDLR) is delivered with an AAV8 vector in patients that are LDLR negative (NCT02651675), it should be possible to perform positron emission tomography-computer tomography (PET-CT) with an isotope labeled antibody against LDLR. Such analyses promise to yield a detailed map of LDLR expression and, hence, AAV8 tissue tropism in human individuals. Moreover, even in patients that express normal levels of a nonfunctional LDLR treatment with an AAV vector encoding the LDLR, PET-CT should allow the determination of expression levels of LDLR in non-target organs.
However, the majority of current AAV gene therapy is aimed at either expressing secreted or intracellular proteins, which makes similar PET-CT studies impossible. But, at least in principle, a general approach to predict the tropisms of various AAVs in humans exists, namely the comparison of AAV serotypes and variants encoding a marker protein. Maybe the most obvious choice for such marker protein experiments would be PET-CT with herpesvirus thymidine kinase (HSV-TK) as a reporter protein and the fluoride-18-labeled compound 9-(4-[
18 F]fluoro-3-[hydroxymethyl]butyl)guanine, [
18 F]FHBG, as thymidine kinase substrate. However, AAV injection can trigger the long-term expression of HSV-TK, a protein that is antigenic. In fact, it has been shown that the systemic injection of AAV5-(HSV-TK) into nonhuman primates results in only transient HSV-TK expression in the liver owing to a cellular immune response against HSV-TK. It is noteworthy, however, that despite this cellular immune response, which presumably resulted in the elimination of transduced hepatocytes, the only change in liver enzymes was an increase of aspartate aminotransferase at days 7, 15 or 30 over the course of the 90-day experiment. 8 Alternative methods to measure noninvasively in vivo transduction with AAV vectors using different, less immunogenic marker proteins are unquestionably conceivable, making such studies less risky. Even so, marker gene experiments undoubtedly put patients' health at risk without the potential of therapeutic benefits, which raises unique ethical challenges. It is, of course, true that we perform phase I trials in healthy individuals in large numbers every day, and that these trials are not without risks. In fact, numerous clinical trials have been terminated early in the past because of a lack of benefit and sometimes serious adverse events, including treatment-related deaths. But, one can reasonably argue that phase I trials with small-molecule drugs or biologicals with a short half-time are qualitatively different from marker gene studies with AAV vectors. After all, even if there are no adverse events in the short term, we will most likely permanently alter what genes this individual will express. It is simply impossible to predict what future consequences this might have. In addition, the individual would likely raise a strong humoral immune response against the AAV vector. The resulting neutralizing antibodies would almost certainly render these individuals ineligible for any future AAV gene therapeutic treatment from which they might otherwise benefit. Which raises the question: is it ethical to perform AAV gene marker study experiments in healthy individuals? This is a difficult question, for which there are no clear cut answers. If not, what are the alternatives? Currently, the placebo control in phase II AAV gene therapy trials is most often a saline injected group. Would it be ethical to include an additional arm in a phase II trial in which a small number of patients would be injected with a vector of the same serotype used in the trial, but that encodes a marker gene?
Without a doubt, AAV marker gene trials are fraught with significant ethical challenges. But, does the failure to perform trials with marker genes not also raise ethical questions? For instance, is it in the best interest of patients to perform clinical trials with AAV vectors whose tropism we do not know? For many gene therapeutic treatments the exclusive expression of a therapeutic transgene in a specific tissue or cell type is likely not critical. However in other settings, for instance in the gene therapeutic treatment of certain neurological disorders, the cell type-specific expression of the therapeutic gene is doubtlessly essential. Similarly, the expression of 'biological beta-blockers' or 'biological pace makers' likely shows the best treatment potential if the expression is restricted to specific regions of the heart, such as the sinoatrial node. 9 In fact, for the treatment of certain disorders, the extraneous expression of a biologically active, therapeutic transgene arguably poses a much higher risk to patients than the expression of a 'biologically inactive' marker protein.
In conclusion, unfortunately, there is no easy answer as to whether the risks of marker gene trials outweigh their potential benefits. But I posit that, as a field, we owe it to our potential patients to start having serious discussions about how we will tackle this difficult topic. Hopefully, this article can spark a conversation among all of us on how to start addressing the question if and how we should include studies aimed at determining the tropism of AAV into future clinical trials.
